Skip to main content

Table 1 Summary of clinical trials using CAR T cell mesothelin-targeted immunotherapies in various solid tumor

From: Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment

Target

Intervention

Phase

Treated Cancers

Primary outcome measures

Clinical Trials Identifier

Status

Mesothelin

CAR T cells alone

I

Metastatic pancreatic ductal adenocarcinoma (PDAC)

Number of adverse events

NCT01897415

Completed (Well-tolerated and showed preliminary evidence of antitumor efficacy in pancreatic cancer)

CAR T cells + fludarabine, cyclophosphamide & aldeslekin

I/II

Metastatic cancers (PDAC, cervical, lung, ovarian & mesothelioma)

Frequency and severity of adverse events & objective response rate (ORR)

NCT01583686

Recruiting

CAR T cells with/without cyclophosphamide

I

Unresectable/ Metastatic PDAC

Number of participants with adverse events

NCT03323944

Active, not recruiting

CAR T cells with/without cyclophosphamide

I

Metastatic PDAC, epithelial ovarian cancer, & mesothelioma

Number of adverse events

NCT02159716

Completed

(No acute adverse events were observed)

CEA

Anti-CEA CAR-T cells

Ib

Liver metastases

Number of participants with adverse events

NCT02850536

Active, not recruiting

II

Metastatic colorectal cancer

Number of participants with adverse events

NCT02959151

Recruiting

I

Lung cancer

Colorectal cancer

Gastric cancer

Breast cancer

PDAC

Toxicity profile and number of participants with adverse events

NCT02349724

Recruiting

I

PDAC

Number of patients with tumor response

NCT03267173

Recruiting

MUC-1

Anti-MUC-1 CAR T cells

I/II

Hepatocellular carcinoma

Non-small cell lung cancer

PDAC

Triple-negative invasive breast cancer

Adverse events associated with the administration of anti-MUC-1 CAR T cells

NCT02587689

Recruiting

I/II

Malignant glioma of brain

Colorectal cancer

Gastric cancer

Adverse events associated with the administration of anti-MUC-1 CAR T cells

NCT02617134

Recruiting

Anti-CTLA-4/PD-1 expressing MUC1-CAR-T cells

I/II

Advanced solid tumor

Safety profile of CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells

NCT03179007

Recruiting

FAP

Adoptive transfer of re-directed FAP-specific T cells

I

Malignant pleural mesothelioma

Safety profile

NCT01722149

Active, not recruiting